Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab-680LT fluorescence endoscopy in locally advanced esophageal cancer
NL-OMON51996Phase 1Terminated
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab-680LT in esophageal cancer, sponsored by University Medical Center Groningen. Primary endpoint: Safety and feasibility of quantitative fluorescence endoscopy with durvalumab-680LT. Started Apr 2023; status: terminated.
02
Drugs
durvalumab-680LT
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NL-OMON51996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51996.